Etavopivat

Etavopivat, in the phase 2 HIBISCUS trial, showed improvements in vaso-occlusive crises, fatigue, hemolysis, and hemoglobin levels in sickle cell disease patients, with a significant reduction in VOCs in per-protocol analysis. The drug's novel mechanism of action as an erythrocyte pyruvate kinase activator suggests potential benefits for SCD treatment.

Phase 2 HIBISCUS study shows etavopivat may decrease vaso-occlusive crises in sickle cell disease, with trends of lower VOC incidence over 52 weeks and higher hemoglobin response at 24 weeks compared to placebo. Phase 3 HIBISCUS trial to confirm findings.

Phase 2 HIBISCUS study results indicate etavopivat may reduce vaso-occlusive crises in sickle cell disease, with trends of reduced VOC incidence over 52 weeks and increased hemoglobin response at 24 weeks vs. placebo. Results to be confirmed in phase 3 HIBISCUS trial.

Phase 2 data from the HIBISCUS study indicates etavopivat may reduce vaso-occlusive crises in sickle cell disease, with a trend towards lower VOC incidence and increased hemoglobin response. Results will be further tested in the phase 3 HIBISCUS trial.

Recent studies presented at the ASH Annual Meeting highlight advancements in treating sickle cell disease (SCD) and immune thrombocytopenia (ITP). Key findings include a new oral medication for ITP showing durable platelet response, etavopivat reducing SCD pain episodes by nearly half, hydroxyurea benefits for HbSC SCD variant, safe fertility preservation for SCD patients, and promising early results from a base-edited gene therapy for SCD.

Etavopivat, a pyruvate kinase activator, showed efficacy in a 52-week phase 2 trial for sickle cell disease, reducing vaso-occlusive crisis rates and increasing hemoglobin levels. Participants aged 12–65 with SCD were randomized to etavopivat 200 mg, 400 mg, or placebo. Etavopivat groups had lower VOC rates and higher Hb responses compared to placebo, with improvements in hemolysis biomarkers and fatigue. Adverse events were mostly mild to moderate.

Phase 2 results of the HIBISCUS study show etavopivat may reduce vaso-occlusive crises and increase hemoglobin response in sickle cell disease patients, with phase 3 trials underway. Etavopivat demonstrated lower VOC rates and higher hemoglobin response compared to placebo, indicating potential for improved treatment options.

Novo Nordisk's phase 2 HIBISCUS study on etavopivat showed reduced vaso-occlusive crises and increased hemoglobin response in sickle cell disease patients over 52 weeks. Results, indicating potential for symptom and disease progression management, await phase 3 confirmation.

Phase 2 results from the HIBISCUS study show etavopivat may reduce vaso-occlusive crises and increase hemoglobin response in sickle cell disease patients, with phase 3 trials underway to confirm findings.